**Supplementary Table 1.** Statements regarding certolizumab pegol, golimumab, vedolizumab and ustekinumab concentrations to target.

|  |  |  |
| --- | --- | --- |
| **Statement\*** | **Vote agreement, %** | **Strength of recommendation\*\*** |
| 40. Certolizumab pegol concentrations to target at week 6 should be at least 32-36 μg/ml. | 100  | 8.1 |
| 41. Certolizumab pegol concentrations to target during maintenance therapy should be at least 13-15 μg/ml. | 80 | 7.5 |
| 42. Golimumab concentrations to target at week 6 should be at least 3-7 μg/ml. | 100 | 8.3 |
| 43. Golimumab concentrations to target during maintenance therapy should be at least 1-3 μg/ml. | 80 | 7.5 |
| 44. Vedolizumab concentrations to target at week 6 should be at least 33-37 μg/ml.  | 100 | 8.8 |
| 45. Vedolizumab concentrations to target at week 14 should be at least 15-20 μg/ml. | 80 | 7.5 |
| 46. Vedolizumab concentrations to target during maintenance therapy should be at least 10-15 μg/ml. | 90 | 7.7 |
| 47. Ustekinumab concentrations to target at week 8 should be at least 3-7 μg/ml. | 100 | 8.7 |
| 48. Ustekinumab concentrations to target during maintenance therapy should be at least 1-3 μg/ml.  | 100 | 8.3 |

\*For all statements the upper limit of range typically refers to drug concentration associated with more stringent therapeutic outcomes such as biochemical, endoscopic, histologic and composite remission defined as any combination of the previous. \*\*Mean score of rating of the statements.